Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 112

Results For "24"

2054 News Found

Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr
News | August 12, 2024

Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr

Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore


Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr
News | August 12, 2024

Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr

Revenue from operations stood at Rs. 313.4 crore during Q1 FY25


Zydus receives final approval from USFDA for Valbenazine Capsules
Drug Approval | August 11, 2024

Zydus receives final approval from USFDA for Valbenazine Capsules

Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)


Caplin Point announces completion of unannounced USFDA inspection
Drug Approval | August 11, 2024

Caplin Point announces completion of unannounced USFDA inspection

The inspection was concluded with zero observations


HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr
News | August 11, 2024

HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr

Our centers are performing as expected or even better


Merck to acquire investigational B-Cell depletion therapy from Curon Biopharmaceutical
News | August 11, 2024

Merck to acquire investigational B-Cell depletion therapy from Curon Biopharmaceutical

CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases


Granules India receives ANDA approval for Trazodone Tablets
Drug Approval | August 11, 2024

Granules India receives ANDA approval for Trazodone Tablets

Trazodone tablets are indicated for the treatment of major depressive disorder in adults


Aurobindo posts Q1 FY25 PAT higher by 61% at Rs. 7,567 Cr
News | August 11, 2024

Aurobindo posts Q1 FY25 PAT higher by 61% at Rs. 7,567 Cr

Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses


Jan Aushadhi Kendras have sold Rs. 5,600 Cr medicines over last 10 years
Policy | August 10, 2024

Jan Aushadhi Kendras have sold Rs. 5,600 Cr medicines over last 10 years

The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024


IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
News | August 10, 2024

IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr

The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24